1783 — Maxigen Biotech Balance Sheet
0.000.00%
- TWD3.76bn
- TWD3.12bn
- TWD680.65m
- 93
- 32
- 79
- 80
Annual balance sheet for Maxigen Biotech, fiscal year end - December 31st, TWD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 210 | 540 | 801 | 433 | 641 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 100 | 114 | 100 | 97.1 | 104 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 432 | 784 | 993 | 620 | 830 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 482 | 465 | 437 | 430 | 433 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 956 | 1,265 | 1,448 | 1,493 | 1,582 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 86.6 | 116 | 152 | 131 | 206 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 96.2 | 123 | 152 | 132 | 207 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 860 | 1,142 | 1,296 | 1,361 | 1,375 |
Total Liabilities & Shareholders' Equity | 956 | 1,265 | 1,448 | 1,493 | 1,582 |
Total Common Shares Outstanding |